Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
This study will determine whether CT-P6 and Herceptin are equivalent in patients with
early-stage breast cancer undergoing neoadjuvant chemotherapy. Our hypothesis is that the
pathologic complete response rate will be equivalent in patients treated with neoadjuvant
CT-P6 or Herceptin. Patients will receive 8 cycles of neoadjuvant systemic therapy and up to
10 cycles of therapy in the adjuvant setting.